Gold prices bounce off 3-week lows; demand likely longer term
Roxanne Lagano, Executive Vice President at Zoetis Inc . (NYSE:ZTS), recently executed a sale of company stock. According to a recent SEC filing, Lagano sold 326 shares of Zoetis common stock at a price of $171.18 per share, totaling $55,804. This transaction was part of a pre-established trading plan under Rule 10b5-1, which Lagano adopted in September 2024. The sale comes as Zoetis, currently valued at $78.7 billion, trades near its Fair Value according to InvestingPro analysis, with the stock showing historically low price volatility.
In addition to the sale, Lagano engaged in several other transactions on February 8, 2025. She acquired common stock upon the vesting and settlement of restricted stock units (RSUs), resulting in the acquisition of 597 and 1,404 shares, respectively. These acquisitions did not involve any cash transactions. With Zoetis’s earnings report due on February 13, investors should note that the company maintains a "GREAT" financial health score and has consistently maintained dividend payments for 13 consecutive years.
Lagano also disposed of 226 and 464 shares to cover tax obligations at a price of $171.43 per share, resulting in a total transaction value of $118,286. Following these transactions, Lagano holds 16,107 shares of Zoetis common stock directly. The company’s strong financial position is reflected in its healthy current ratio of 3.69, indicating robust liquidity to meet short-term obligations.
In other recent news, Zoetis Inc. has seen a flurry of activity. BTIG analysts have maintained a Buy rating on the company’s shares, setting a target price of $225, citing robust growth potential driven by new product launches. Meanwhile, Stifel analysts have also backed Zoetis with a Buy rating, adjusting their price target to $180 as they anticipate the resilience of key franchises and projected near all-time high revenue growth.
Zoetis has announced a quarterly dividend of $0.50 per share for Q2 2025, reflecting the company’s stable financial performance and commitment to returning value to shareholders. In another development, Zoetis has updated the label for its canine osteoarthritis pain control product, Librela, following a review of post-approval experiences. The company remains confident in Librela’s safety and efficacy despite some investor concerns.
In their reports, both BTIG and Stifel analysts have addressed potential impacts on the performance of Zoetis’s stock, such as decreased pet visits and the recent FDA label update on Librela. Both firms anticipate continued success for Zoetis, underlining the company’s potential for growth in the rapidly evolving animal health market. These developments highlight Zoetis’s ongoing activities and strategies in maintaining its position in the global animal health industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.